BioVie announced that a data abstract from its Phase 2 open label trial evaluating NE7107 in degenerative dementias has been accepted for presentation at the 78th Annual Scientific Convention of the Society of Biological Psychiatry, to be held in San Diego, CA April 27-29, 2023. Details for the presentation are as follows: Effects of NE3107 on Depression and Multimodal Outcomes in a Phase 2, Open-Label Study in Patients with Cognitive Decline Due to Degenerative Dementias
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BIVI:
- BioVie To Present Data from NE3107 Phase 2 Open-Label Trial at Society of Biological Psychiatry Annual Meeting
- BioVie to hold a virtual event
- BioVie announces data from Phase 2 PD trial
- BioVie Announces Data from Phase 2 Parkinson’s Disease Trial Accepted for Presentation at AD/PD 2023
- BioVie Announces Registration Details for “BioVie Day” Webinar